Yahoo Web Search

  1. Eli Lilly and Company (NYSE:LLY) is about to trade ex-dividend in the next 3 days. Eli Lilly's upcoming dividend is US$0.65 a share, following on from the ...

  2. Based in Indianapolis, Eli Lilly (LLY) is in the Medical sector, and so far this year, shares have seen a price change of -2.85%. Eli Lilly has increased its dividend ...

  3. Top Stock Reports: Disney, Eli Lilly, ADP & More

    Zacks via Yahoo FinanceAug 08 15:21 PM

    You can see all of today's research reports here >>> Disney's shares have gained +23% year to date, underperforming the Zacks Media Conglomerates industry's gain of +29.8%. Disney's third-quarter ...

  4. Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study

    Zacks via Yahoo FinanceAug 14 13:24 PM

    Eli Lilly & Company LLY announced superiority of its plaque psoriasis drug Taltz over J&J’s JNJ new drug, Tremfya (guselkumab), in delivering total skin clearance at week ...

  5. Eli Lilly And Co (NYSE: LLY) reported positive data for its plaque psoriasis drug Tuesday in a head-to-head comparison study with Johnson & Johnson (NYSE: JNJ)'s Janssen unit's ...

  6. 3 Lung Cancer Stocks That Could Soar in September

    Motley Fool via Yahoo FinanceAug 04 19:04 PM

    Eli Lilly (NYSE: LLY), Amgen (NASDAQ: AMGN), and AstraZeneca (NYSE: AZN) are scheduled to present hotly anticipated results that could expand their presence in this important niche ...

  7. Please note that United Therapeutics bought exclusive rights to commercialize Adcirca (tadalafil) for the treatment of PAH in the United States from Eli Lilly LLY in November 2008 ...

  8. Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates

    Zacks via Yahoo FinanceAug 05 14:46 PM

    Shares of Aduro BioTech, Inc. ADRO were down around 3.6% on Friday after it announced second-quarter 2019 results on Aug 1. In fact, so far this year, the stock has plunged 48.9%, underperforming the industry's decrease of 1.8%.

  9. Verastem Inc (VSTM) Q2 2019 Earnings Call Transcript

    Motley Fool via Yahoo FinanceAug 05 17:13 PM

    At this time, I would like to introduce Mr. John Doyle, Vice President of Investor Relations and Finance at Verastem Oncology. Welcome, everyone, and thank you for joining us this afternoon ...

  10. Celldex Therapeutics, Inc. CLDX incurred adjusted second-quarter 2019 loss (excluding gain on fair value re-measurement of contingent consideration) of 92 cents per share, narrower than the ...

  1. Ads
    related to Eli Lilly & Company